Dyax Corp.

Antibodies enter clinical trials at ImClone Systems

Published in Drug Law Weekly, February 8th, 2005

Dyax Corp. (DYAX) announced that two fully human monoclonal antibodies that were derived from Dyax's proprietary phage display libraries have entered into phase I clinical development at ImClone Systems, as recently reported by the Dyax library licensee.

ImClone Systems reported that the antibodies, IMC-11F8 and IMC-1121B, both of which target growth factor receptors, are being evaluated for their potential as cancer therapeutics. Each antibody was isolated by ImClone Systems using an antibody-fragment (Fab) phage display library licensed to the company by Dyax, and then further optimized by ImClone Systems.

Henry E. Blair, chairman, president and...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Law Weekly

Source: Drug Law Weekly (2005-02-08)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry